Rein Therapeutics Inc. (RNTX)
RNTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1420565/000119312526126385/0001193125-26-126385-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RNTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001420565 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$49.9M |
| Operating income | -$50.6M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $3.2M |
| Total assets | $24.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-14 |
| Cash and burn | $8.5M cash; operating cash flow -$4.7M a quarter. | Report 2026-06-30 |
| Shares outstanding | 86,267,032 (2026-08-12); 23,305,108 a year earlier; 4,541,167 three years earlier. | Cover page 2026-08-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-05-04 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-08-27 |
| Auditor | CBIZ CPAs P.C., New York, New York, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $625K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $0 | -$6.4M | -$8.6M | $8.5M | No debt tags | $0 | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $0 | -$5.8M | -$3.4M | $4.4M | $4.9M | $0 | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $0 | -$32.0M | -$3.2M | $3.2M | $0 | $0 | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | $0 | -$5.6M | -$3.5M | $4.0M | No debt tags | $0 | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $0 | -$6.8M | -$6.4M | $5.7M | No debt tags | $0 | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $0 | -$5.5M | -$6.2M | $7.4M | No debt tags | $0 | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $0 | -$41.0M | -$4.8M | $12.9M | No debt tags | $0 | 10-K 2026-03-26 |
| Q3 2024 2024-09-30 | $0 | -$5.8M | -$3.8M | $17.7M | No debt tags | $0 | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-04 |
| Latest annual report | 10-K/A | 2026-04-27 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-06-08 |
Source: SEC EDGAR submissions feed, 527 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -10.1% |
| 1 month | -26.9% |
| 3 months | -29.9% |
| Year to date | -52.4% |
| 1 year | -59.1% |
| From 52-week high | -70.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OSTX | OS Therapies Incorporated | $0.6807 | -8.63% | $35.4M |
| TELO | Telomir Pharmaceuticals Inc. | $0.4810 | -1.96% | $35.4M |
| VERU | Veru Inc. | $2.08 | -0.48% | $35.5M |
| ATHE | Alterity Therapeutics Limited | $1.96 | 0.00% | $35.7M |
| GRCE | Grace Therapeutics Inc. | $1.75 | -3.31% | $36.8M |
| NNVC | NanoViricides Inc. | $1.24 | +0.81% | $31.7M |
| SER | Serina Therapeutics Inc. | $1.42 | +2.16% | $37.7M |
| BMEA | Biomea Fusion Inc. | $0.5201 | -10.67% | $37.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier